Before joining Crescendo, Pavel was the Head of Translational Medicine at Roche and Genentech where he led over 50 programs through early and late clinical development. As both a physician and a scientist, he has in-depth knowledge of the real-life experimental and clinical challenges associated with delivering highly innovative medicines and has successfully translated scientific findings into transformative medicines such as Avastin and Gazyva, leading to significant improvement in the lives of cancer patients.
Pavel has a distinguished academic, clinical and scientific career at world-leading medical institutions. He was Professor of Clinical Experimental Oncology at the Karolinska Institutet, Stockholm and has held positions at NIH, MD Anderson Cancer Center and Scripps Research Institute. He is the author of 115 highly-cited publications and patents within tumour immunology. Pavel holds a medical degree and a doctorate in medicine in Natural Killer Cells in the clinic from Charles University, Prague, as well as a PhD in Immunology from the Karolinska Institutet.
Humabody® is a registered trademark of Crescendo Biologics Ltd.